Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | PRKD1 | Q15139 | 6/20 | 0.43 |
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8143330 | 1.00 | USP30 (0.48) | USP30PIK3CDGPR119PIK3CAPRKD1 | |
| SCHEMBL8130742 | 1.00 | USP30 (0.48) | USP30PIK3CDGPR119PIK3CAPRKD1 | |
| SCHEMBL1424326 | 0.88 | PRKD1 (0.58) | PRKD1PRKCAPRKCDSYK | |
| SCHEMBL1424331 | 0.88 | PRKD1 (0.58) | PRKD1PRKCAPRKCDSYK | |
| SCHEMBL1424330 | 0.88 | PRKD1 (0.58) | PRKD1PRKCAPRKCDSYK | |
| SCHEMBL15645395 | 0.86 | PIK3CD (0.48) | USP30PIK3CDPIK3CA | |
| SCHEMBL15645393 | 0.86 | PIK3CD (0.48) | USP30PIK3CDPIK3CA | |
| SCHEMBL1424181 | 0.84 | PRKD1 (0.55) | USP30PRKD1PRKCAPRKCD | |
| SCHEMBL1424057 | 0.84 | PRKD1 (0.55) | USP30PRKD1PRKCAPRKCD | |
| SCHEMBL1424054 | 0.84 | PRKD1 (0.55) | USP30PRKD1PRKCAPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142685-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| US-20120142685-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| US-20120142685-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| EP-2144909-B1 | [2,6]NAPHTHYRIDINES USEFUL AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142685-A1 | ORGANIC COMPOUNDS | MARK1, PKN1, MARK2 | USP30 3526/4885PIK3CD 501/4885GPR119 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.